RE:CRH EarningsI think the key here is the strong Adj EBITDA to SH - the full year was obviously impacted by COVID but a run rate of ~$40MM/year is huge for WELL and will give the company some cashflow to leverage in the form of more debt for acquisitions
Fourth quarter 2020 highlights (all results expressed in USD):
- Total revenue of $36.8 million, an increase of 21% from fourth quarter 2019
- Anesthesia services revenue of $34.1 million, an increase of 24% from fourth quarter 2019
- Anesthesia patient cases of 108,681 increased 15% from fourth quarter 2019
- Adjusted operating EBITDA of $16.1 million, a 44% adjusted operating EBITDA margin
- Adjusted operating shareholder EBITDA of $11.2 million, an increase of 27% from fourth quarter 2019
Year-end highlights (all results expressed in USD) – Q1 to Q3 significantly impacted by COVID 19:
- Total revenue of $106.2 million, a decrease of 12% over 2019
- Anesthesia services revenue of $97.7 million, a decrease of 11% over 2019
- Anesthesia patient cases of 323,644, a decrease of 6% over 2019
- Adjusted operating EBITDA of $42.4 million, a 40% adjusted operating EBITDA margin
- Adjusted operating shareholder EBITDA of $28.7 million, a decrease of 22% from 2019